Merck -- How the Business Works
Merck is a $298.8B diversified pharmaceutical company whose business model centers on
blockbuster drug franchises, a deep clinical pipeline, and a stable animal health division.
The dominant revenue engine is KEYTRUDA, a PD-1 checkpoint inhibitor that generated $31.6B
in 2025 -- roughly 49% of total company revenue and the single largest drug franchise in the
world. Beyond oncology, Merck operates a vaccines business (GARDASIL HPV, VAXNEUVANCE
pneumococcal), an emerging cardiovascular franchise (Winrevair for PAH), and an animal health
segment (~10% of revenue). FY2025 total revenue was $65.0B (+1.3% YoY). The defining strategic
challenge is the KEYTRUDA loss of exclusivity (LOE) in 2028-2029 -- the largest single-product
patent cliff in pharmaceutical history. Management is pursuing subcutaneous KEYTRUDA (patents
to 2042), ADC partnerships, and pipeline diversification to bridge the gap. Calendar FY (Dec FYE).
Composite score 5.8/10 (Watchlist -- borderline HOLD/AVOID).
Price / Composite Score
$120.87 / 5.8
Watchlist -- near 52-week highs, up 65% from lows
FY2025 Revenue
$65.0B
+1.3% YoY | KEYTRUDA $31.6B (49% of total)
Trailing P/E
16.6x
EPS TTM $7.28 | Dividend yield 2.81%
Key Risk
LOE 2028
KEYTRUDA patent cliff -- largest LOE in pharma history
Revenue mix -- KEYTRUDA dominance defines the business
Product Revenue Breakdown (FY2025)
KEYTRUDA (~49% of Revenue)
$31,640M
PD-1 checkpoint inhibitor -- 20+ approved indications
+7.3% YoY | ~55-60% global PD-1/PD-L1 market share
Animal Health (~10%)
$6,354M
Companion animal + livestock
+8.1% YoY -- steady, diversifying
Vaccines + Other (~41%)
$27,017M
GARDASIL $5.2B, Winrevair $1.4B, Lagevrio $380M, other pharma
GARDASIL -39% YoY (China headwinds) | Winrevair +244%
KEYTRUDA ~49%
Animal Health ~10%
GARDASIL ~8%
Winrevair ~2%
Other Pharma ~31%
Winrevair Quarterly Ramp -- First-in-Class PAH Launch
Q2 2024 (Launch)
$70M
Launch quarter
Q4 2024
$200M
+186% QoQ
Q4 2025
$467M
~$1.9B annualized run-rate
Peak Sales Est.
$3-5B
Only disease-modifying PAH agent
KEYTRUDA concentration is the defining feature and the defining risk.
At 49% of total revenue, KEYTRUDA is the largest single drug franchise in the world --
approximately 2.5-3x the size of its nearest PD-1 competitor (Opdivo at ~$9-10B). This
dominance generates enormous cash flows today but creates an existential patent cliff in
2028-2029. Winrevair is the most promising diversification asset, ramping faster than
consensus expected, but even at $3-5B peak it replaces only 10-16% of KEYTRUDA revenue.
GARDASIL, once a $8.6B growth engine, declined 39% in 2025 due to China competition.
Revenue data from Merck 10-K/10-Q filings and Daloopa. Product revenue breakdown from FY2025 earnings release. Winrevair quarterly data from earnings call commentary.
How Merck makes money -- the pharma value chain
Merck Value Chain -- From Discovery to Recurring Prescriptions
R&D / Discovery
Internal + M&A + partnerships
$31B+ R&D spend over 3 years
→
Clinical Trials
Phase I-III, label expansions
KEYTRUDA: 20+ approved indications
→
Regulatory / Launch
FDA/EMA approvals, label expansion
SC KEYTRUDA approved -- patents to 2042
→
Commercial / Sales
Global sales force, KOL relationships
Oncology is spec-pharma -- high-value prescribers
→
Patent Protection
Exclusivity period = pricing power
Core KEYTRUDA patent expires 2028
Business Model Unit Economics and Scale
$31.6B
KEYTRUDA FY2025 Revenue
+7.3% YoY -- world largest drug
55-60%
PD-1/PD-L1 Market Share
Dominant in $48.5B checkpoint market
$1.4B
Winrevair FY2025
Fastest big pharma launch in years
2.81%
Dividend Yield
Consistent payer -- cash flow generative
KEYTRUDA market share estimates from analyst reports and management commentary. Winrevair revenue from Daloopa. Dividend yield as of April 2026.
Competitive landscape -- oncology oligopoly with looming LOE
Competitive Position Assessment (Oligopoly Gate: PASS -- PD-1 Market)
| Drug / Company | Est. 2025 Revenue | PD-1/PD-L1 Share | Competitive Dynamic |
|---|---|---|---|
| Checkpoint Inhibitor Market (~$48.5B, Growing to $73B by 2030) | |||
| KEYTRUDA (Merck) | ~$31.6B | ~55-60% | Dominant -- standard of care in NSCLC 1L, 20+ indications |
| Opdivo (BMS) | ~$9-10B | ~17-19% | Nearest competitor -- strong in renal, melanoma, adjuvant settings |
| Imfinzi (AstraZeneca) | ~$4-5B | ~8-10% | Growing in NSCLC and SCLC; gaining share in combinations |
| Tecentriq (Roche) | ~$3-4B | ~6-8% | Mature, lower growth vs. peers |
| Others (incl. China PD-1s) | ~$5-6B | ~10-12% | China domestic PD-1s at steep discounts -- limited ex-China impact |
| Vaccines -- GARDASIL Facing China Competition | |||
| Innovax Cecolin 9 (China) | Emerging | Structural threat | Domestic 9-valent HPV at ~60% price discount -- permanently compresses GARDASIL in China |
| Post-LOE Biosimilar Threat (2028+) | |||
~55-60%
PD-1/PD-L1 Market Share
2.5-3x nearest competitor
20+
Approved Indications
NSCLC 1L standard of care
2028
Core Patent Expiry
~$24B annual revenue at risk
SC 2042
Subcutaneous Patent Life
Target 30-40% US conversion by 2027
Oligopoly gate: PASS today, but time-limited.
KEYTRUDA commands ~55-60% of the $48.5B global PD-1/PD-L1 market and is the undisputed
standard of care in NSCLC first-line, the largest oncology indication by patient volume.
However, the core compound patent expires in 2028, with method-of-use extensions to 2029.
Post-LOE, estimated ~80% revenue erosion (~$24B annual loss) without mitigation.
Subcutaneous KEYTRUDA (approved, patents to 2042) is the primary defense -- management
targets 30-40% SC conversion of the US patient base by 2027, potentially preserving
$9-12B per year. This is credible but unproven at scale.
Market share estimates from analyst reports and Merck investor presentations. Competitive data from BMS, AstraZeneca, and Roche earnings releases. LOE analysis from 10-K filings.
Growth vectors and pipeline strategy
Revenue Diversification and Post-LOE Bridge Strategy
| Growth Vector | Timeline | Revenue Potential | Detail |
|---|---|---|---|
| SC KEYTRUDA Conversion | Now - 2027 | $9-12B preserved | Approved SC formulation with patents to 2042. Target 30-40% US conversion. Key LOE mitigation strategy |
| Winrevair (PAH) | Now | $3-5B peak | First-in-class, $1.9B annualized run-rate. PAH market ~$9.3B by 2034. Label expanding (ZENITH trial) |
| ADC Pipeline (Daiichi/Kelun) | 2027-2030 | TBD (binary) | $22B Daiichi partnership for 4 DXd ADCs. Kelun partnership for 7 preclinical ADCs. ADC market ~$16B by 2030 |
| Oncology TAM Growth | Secular | $73B by 2030 | Checkpoint inhibitor market growing from ~$48.5B to ~$73B. Even post-LOE, oncology TAM expands |
| GARDASIL Recovery (ex-China) | 2026+ | Stabilization | Ex-China franchise stable with secular tailwinds. China structurally impaired by domestic competitors. Male indication approval helps |
| Animal Health | Steady | Mid-single-digit growth | $6.4B, +8.1% YoY. Companion animal trends secularly positive. Diversifying but not a catalyst |
Management claims line of sight to $70B+ of commercial opportunity by mid-2030s
vs. consensus peak KEYTRUDA of ~$35B. The bridge requires SC conversion success, Winrevair
reaching peak sales, ADC pipeline clinical success, and continued organic growth across
the portfolio. The 2028-2031 period will be a revenue trough regardless of execution --
the question is the depth and duration of the valley.
Pipeline and growth vector data from Merck investor presentations, earnings calls, and Daloopa. ADC partnership terms from deal announcements. PAH market projections from industry research.
Key risks to the business model
| Risk | Timeframe | Severity | Detail |
|---|---|---|---|
| KEYTRUDA LOE 2028-2029 | ~2 years | Critical | 49% of revenue at risk. Estimated ~80% post-LOE erosion = ~$24B annual loss. Largest single-product cliff in pharma history |
| SC Conversion Execution | 2025-2028 | High | SC KEYTRUDA must reach 30-40% conversion to preserve $9-12B. Physician and payer adoption rates are unproven at this scale |
| GARDASIL China Impairment | Structural | High | -39% YoY decline driven by domestic Chinese 9-valent HPV vaccines at 60% price discounts. This is permanent, not cyclical |
| ADC Pipeline Binary Risk | 2026-2028 | Moderate | $22B+ committed to ADC partnerships. Revenue contribution 3-5 years away. Clinical readouts create binary event risk |
| Single-Product Concentration | Ongoing | Moderate | KEYTRUDA at 49% of revenue creates extreme sensitivity to any demand, pricing, or competitive disruption in checkpoint inhibitors |
| Revenue Trough 2028-2031 | Medium-term | High | Even with successful diversification, the 2028-2031 period will see a material revenue decline. Depth of trough is the key variable |
Risk assessment from Merck 10-K, earnings calls, and analyst commentary. LOE timeline from patent analysis. GARDASIL China data from FY2025 earnings release.